Editorial team
ioQuanta Research Desk
-
Evidence date ·Treatment paths after immunotherapy for advanced urothelial cancer
Review or Meta-AnalysisA 2021 review found that 25%–35.5% of patients in two studies received another treatment after immunotherapy stopped; treatment paths varied widely.
-
Evidence date ·Why the two-drug melanoma comparison matters beyond older treatments
Review or Meta-AnalysisA 2021 review reports survival gains for nivolumab over chemotherapy and ipilimumab, while leaving open whether adding ipilimumab improves survival further.
-
Evidence date ·Why do scan-reading rules matter during melanoma immunotherapy?
Review or Meta-AnalysisIn a 24-article review, modified PET/CT criteria had 94% pooled sensitivity for early melanoma response assessments, versus 64% with conventional criteria.
-
Evidence date ·What fast mouse scans show, and what a nanobody drug still needs to prove
Review or Meta-AnalysisA labeled nanobody revealed a checkpoint in mouse tumors within an hour. In another mouse test, a nanobody slowed tumor growth but did not outperform an antibody.
-
Evidence date ·When should one immunotherapy drug be used in advanced lung cancer?
Review or Meta-AnalysisA ten-trial review favored using immunotherapy alone first in advanced lung cancer, but its separate survival estimates cannot show whether starting first helps more.
-
Evidence date ·How did the five-part regimen affect resistant mouse tumors?
Peer-Reviewed PaperIn a mouse colon-tumor study, 67% of mice given a five-part immune regimen had tumors below 300 mm³, compared with at most 22% given shorter combinations.
-
Evidence date ·How could a dendritic-cell vaccine and nivolumab work together?
Review or Meta-AnalysisA 2021 review describes how dendritic-cell vaccines aim to rally cancer-fighting cells while nivolumab blocks a checkpoint that can blunt their attack.
-
Evidence date ·Why has one immune treatment helped while others face barriers in neuroblastoma?
Review or Meta-AnalysisDinutuximab improved outcomes in neuroblastoma, but a review finds few T and NK cells inside high-risk tumours and explores why broader immune therapies struggle.
-
Evidence date ·How can a possible immune side effect reach the oncology team?
Review or Meta-AnalysisTracked over timeAcross seven studies, some programs improved recognition of possible immune side effects; calls and electronic reports gave patients ways to alert care teams.
-
Evidence date ·How patients and carers helped shape five immunotherapy videos
Peer-Reviewed PaperTracked over timePatients and family carers helped shape five short videos about starting cancer immunotherapy, from infusion preparation to side effects and support.